Skip to main content
All Posts By

Andy

kerecis logo new 1000x1000 1

Arlington’s Kerecis Expands Silicone Fish-Skin Combination Product Range with Shield Spiral, Offering Advanced Customizable Wound Care Solutions

By News

kerecis logo new 1000x1000 1ARLINGTON, Va.–()–Kerecis, the company pioneering the use of sustainably sourced fish skin and fatty acids in cellular therapy and tissue regeneration and protection, today announced the availability of Shield Spiral, an extension of the Kerecis Shield silicone fish-skin combination product range.

The patented, intact fish-skin graft and silicone combination, features perforated fenestration marks cut in a unique spiral pattern, allowing easy customization. The 30 mm graft can be reduced to as small as 15 mm by peeling away the 2 mm outer spiral sections and cutting to the desired size, providing unmatched flexibility and precision in treatment.

Read More
AscentageTakeda250

Ascentage Pharma Received US$100 Million Option Payment from Takeda

By News

AscentageTakeda250ROCKVILLE, Md. and SUZHOU, ChinaJuly 3, 2024 /PRNewswire/ — Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for hematological malignancies, announced today that on July 2, 2024, in relation to the Exclusive Option Agreement with Takeda for the third-generation BCR-ABL inhibitor olverembatinib (HQP1351), Ascentage Pharma has received the US$100 million option payment called for by the Exclusive Option Agreement.

Read More
Sirnaomics

Sirnaomics Announces Interim Results for Successful Completion of the Second Cohort of Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Therapeutics

By News

SirnaomicsHONG KONG and GERMANTOWN, Md. and SUZHOU, ChinaJuly 8, 2024 /PRNewswire/ — Sirnaomics Ltd. (the “Company“, together with its subsidiaries, the “Group” or “Sirnaomics“; stock code: 2257), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today announced the interim results for successful completion of the second cohort of its Phase I clinical study of GalNAc-based RNAi therapeutic STP122G, targeting Factor XI as a novel form of anticoagulation agent.

Read More
early charm logo notxt 1 300x1222

Maryland Awards $500K to Early Charm Ventures for Biomanufacturing Incubator at Harford County Facility

By News

early charm logo notxt 1 300x1222BEL AIR, Md., (July 1, 2024) – Maryland Department of Commerce has awarded $500K to Baltimore-based Early Charm to develop a biomanufacturing incubator at a Harford County-owned facility near Aberdeen Proving Ground (APG). The funding from the state’s Build Our Future grant will be used to upgrade the CONVERGE Innovation Center, formerly known as the HEAT Center, located at the I-95/Aberdeen interchange.

Biomanufacturing is the use of biological processes to build new materials such as body armor made from spider silk, three times the strength of Kevlar. This technology has the potential to revolutionize manufacturing.

Read More
Emergent

Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products

By News

EmergentGAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received more than $250 million in contract modifications from the Administration for Strategic Preparedness and Response (ASPR) at the United States Department of Health and Human Services (HHS), to deliver millions of doses of four medical countermeasures (MCMs). These contract modifications will help ensure continued supply/stockpiling of critical MCMs to address biological threats and emergencies against anthrax, smallpox and botulism.

Read More
EDA

EDA: Biden-Harris Administration Announces Next Funding Round of $504 Million for 12 Tech Hubs Across America

By News

EDAWASHINGTON, DC — The Biden-Harris Administration, through the U.S. Department of Commerce’s Economic Development Administration (EDA), announced another funding round of approximately $504 million in implementation grants to 12 Tech Hubs to scale up the production of critical technologies, create jobs in innovative industries, strengthen U.S. economic competitiveness and national security, and accelerate the growth of industries of the future in regions across the United States.

The Tech Hubs Program is a flagship initiative of President Biden’s Administration to invest in and grow the economies in communities across the country, advancing America’s global leadership in critical technologies, and strengthening our national and economic security.

Read More
cartesiantherapeutics logo

Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing

By News

cartesiantherapeutics logoGAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) — Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of approximately $130.0 million to the Company, before deducting placement agent fees and other offering expenses. The PIPE financing is expected to close on or about July 3, 2024, subject to satisfaction of customary closing conditions.

The PIPE financing included participation from both new and existing investors, including HBM Healthcare Investments (Cayman) Ltd., Invus, Schooner Capital, Surveyor Capital (a Citadel company), Timothy A. Springer, Ph.D., a leading mutual fund manager, and other institutional investors.

Read More
cartesiantherapeutics logo

Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis

By News

cartesiantherapeutics logoGAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) — Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (“Cartesian” or the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced positive topline results from its Phase 2b trial of Descartes-08 in patients with generalized myasthenia gravis (MG).

Descartes-08, Cartesian’s lead product candidate, is an autologous mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T) directed against the B cell maturation antigen (BCMA). It is designed to be administered as an outpatient treatment without the need for lymphodepleting chemotherapy required to achieve activity with conventional CAR-T cell therapies. Descartes-08 was previously granted Regenerative Medicine Advanced Therapy (RMAT) Designation and Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of MG.

Read More
Eyecontrol

TJP: 2023 Crab Trap Finalist EyeControl creates revolutionary medical technology

By News

EyecontrolEyeControl improves clinical outcomes, prevent cognitive decline, and enhance the patient and family experience.“We are honoured to be able to support every patient – but especially our soldiers.”

When Yoav Tzivoni, a combat soldier seriously wounded in the northern Gaza Strip, awoke after six months in the intensive care unit of the Samson Assuta Ashdod University Hospital, he shockingly asked the nurse for his favorite heavy metal music.

“I was shaking from excitement when the nurse texted and said Yoav is asking for his music!” recounts Michal Finkelstein, product specialist, and speech and language pathologist by training, in charge of customer relations and success at the Israeli company EyeControl.

“What? Is he awake?” Finkelstein wondered, saying that she was “shaking from excitement.”

Tzivoni and his fellow wounded ICU soldiers are benefiting from a recently discovered additional and potentially internationally game-changing use of EyeControl, a wearable device that enables patients – including those on ventilators – to communicate with medical staff and family members via eye gestures and a bone conduction headset, to hear the recorded messages of loved ones – and to listen to one’s favorite music.

EyeControl helps improve clinical outcomes, prevent cognitive decline, and enhance the patient and family experience. It is currently being tested in prestigious university hospitals in and out of Israel to see if it reduces delirium in ICU patients.

Click here to read more via TJP.

Prof Z Article

From Tunisia to Maryland: FluoInk’s Journey at the SelectUSA Investment Summit

By News

Prof Z ArticleProfessor Ramzi Maalej, CTO and Founder of FluoInk, recently traveled from Tunisia to Maryland to attend the SelectUSA Investment Summit. FluoInk is currently working on its innovative Bacti Cleaner technology, which adds antibacterial properties to paints. It is making strides in the eco-friendly and non-toxic product space with the development of this product.

BioHealth Innovation Inc. (BHI) is collaborating with FluoInk, along with partners from The Tunisian Health Center for University Research Excellence and Sustainability (CURES) and FHI 360, to help grow their business. While in Maryland, Professor Maalej connected with key figures in the BioHealth Capital Region, including Brian Castleberry, Senior Regional Manager – Middle East, Africa, and UK at the Maryland Department of Commerce, and Brian Darmody, AURP Chief Strategy Officer.

“Visiting Maryland and participating in the SelectUSA Investment Summit was an incredible experience. The networking opportunities and the collaborative environment, facilitated by BHI and FHI 360, were beyond my expectations,” said Professor Ramzi Maalej, CTO and Founder of FluoInk. “This summit has opened new doors for transforming our academic research into impactful commercial products.”

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.